Please assess the completion status of the following clinical trial:

Trial Title: Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-penetrating traumatic brain injury.~2. Age 18 (19 in Alabama) - 70 years.~3. GCS criteria on/off paralytics as specified in protocol~4. Reasonable expectation of completion of outcomes measures at a network center at six months post-injury.~5. Able to swallow oral medication or, if unable to swallow, a gastric tube or peg are placed by 23 hours after injury.~6. Reasonable expectation of enrollment within 24-hour time window.~7. English-speaking~Exclusion Criteria:~1. Intubated patients with GCS motor score = 6 and not meeting CT criteria.~2. Bilaterally fixed and dilated pupils~3. Positive pregnancy test, known pregnancy, or currently breast feeding~4. Evidence of diseases that interfere with outcome assessment~5. Current acetylcholinesterase inhibitor use (Appendix 1)~6. Imminent death or current life-threatening disease~7. Currently enrolled in another study~8. Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Placebo tablets formulated to resemble the citicoline treatment.
- Citicoline (Type: EXPERIMENTAL): Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).